SCHEMBL2117690

SCHEMBL2117690

Cc1ccc(S(=O)(=O)Nc2cc(-c3cccnc3)ccc2C)cc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.61
ABCC1 P33527 1/20 0.61
TSHR P16473 1/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
HTR6 P50406 1/20 0.46
ACLY P53396 2/20 0.46
PIK3CA P42336 2/20 0.46
MTOR P42345 2/20 0.46
KMT2A Q03164 1/20 0.46
PIK3CD O00329 1/20 0.46
PIK3CB P42338 1/20 0.46
PIK3CG P48736 1/20 0.46
PIK3C3 Q8NEB9 1/20 0.46
KIT P10721 1/20 0.45
POLB P06746 1/20 0.45
CKS1B P61024 1/20 0.44
SKP2 Q13309 1/20 0.44
NAMPT P43490 4/20 0.44
CA12 O43570 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119235 0.89 ABCB1 (0.71) ABCB1ABCC1CYP11B1CYP11B2ACLY
SCHEMBL2118244 0.85 ABCB1 (0.51) ABCB1ABCC1CYP11B1CYP11B2HTR6
SCHEMBL2120534 0.85 ABCB1 (0.51) ABCB1ABCC1CYP11B1CYP11B2HTR6
SCHEMBL2118531 0.85 NAMPT (0.55) ABCB1ABCC1HTR6ACLYPIK3CA
SCHEMBL2120599 0.81 KMT2A (0.51) TSHRACLYKMT2AKITPOLB
SCHEMBL12326414 0.78 CYP2A6 (0.54) ABCB1CYP11B1CYP11B2ALDH1A1
SCHEMBL2120627 0.75 TRIM24 (0.59) TSHRACLYKITPOLBALDH1A1
SCHEMBL19039682 0.73 ABCB1 (0.47) ABCB1ABCC1CYP11B1CYP11B2HTR6
SCHEMBL22230481 0.73 TSHR (0.47) TSHRPIK3CAMTORPIK3CDPIK3CB
SCHEMBL2119624 0.72 SLC40A1 (0.47) PIK3CAMTORKMT2APIK3CGPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 ABCB1 2175/4885ABCC1 1204/4885TSHR 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.